Pfizer appoints two senior roles
pharmafile | May 24, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Pfizer, Read
Pfizer has named Olivier Brandicourt as president and general manager of its Emerging Markets and Established Products Business Units, and John Young as president and general manager of its Primary Care Business Unit.
Brandicourt will succeed David Simmons, who is leaving Pfizer to become the chairman and chief executive of Pharmaceutical Product Development Inc. (PPD), a privately held global contract research organisation.
“Olivier is ideally suited to take on this new role,” said Ian Read, Pfizer chairman and chief executive. “He has more than 20 years of global experience in the pharmaceutical industry. Olivier is both a physician and proven business leader who understands the many challenges of today’s changing industry and healthcare landscape.”
Brandicourt has held senior positions at Pfizer across a range of disciplines, including medical and marketing, as well as country and regional management roles in Latin America, Europe, Canada, the UK and the US.
John Young, currently regional president of Europe and Canada for the Primary Care business, will join the company’s executive leadership team. Over his 25-year career with Pfizer, Young has held a number of commercial positions with the company, including country and regional management roles in Australia/New Zealand and the UK.
“John has a deep understanding of the primary care landscape and will be a strong leader for this significant part of our business. We are indeed fortunate to have such a deep bench of talented leaders who can quickly assume new roles and maintain our momentum,” Read added.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
